Ribavirin as maintenance therapy for hepatitis C patients: An interim peacekeeper?

Hepatology

Volumn 38, Issue 1, 2003, Pages 21-24

  Patel, Keyur ^a   Dev, Anouk ^a   Muir, Andrew J ^a   McHutchison, John G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIC C VIRUS RNA; PEGYLATED INTERFERON ALPHA; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG MECHANISM; EDITORIAL; ERADICATION THERAPY; GENOTYPE; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; MAINTENANCE THERAPY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; TH1 CELL; VIREMIA; VIRUS GENOME; VIRUS MUTANT;

EID: 0038122778     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50326     Document Type: Editorial

References (19)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
3. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602.
4. Shiffman ML. Retreatment of patients with chronic hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S128-S134.
5. Davis GL, Fang J, Albrecht J, Goodman Z, the International Hepatitis Interventional Therapy Group. Long-term continuous interferon versus repeated 24-week cycles for disease suppression in IFN-relapsers with chronic hepatitis C [Abstract]. HEPATOLOGY 1999;30(Part 2):317A.
6. Lau JY, Tam RC, Liang JT, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. HEPATOLOGY 2002;35:1002-1009.
7. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, et al. A pilot study of ribavirin therapy for chronic hepatitis C. HEPATOLOGY 1992;16:649-654.
8. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993;19:408-412.
9. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:897-903.
10. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-598.
11. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. HEPATOLOGY 1997;26:473-477.
12. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996;3:247-252.
13. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, Pouyet M, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. HEPATOLOGY 1997;26:500-504.
14. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
16. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998;352:1426-1432.
17. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
18. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994;21:1109-1112.
19. McHutchison JG, Patel K. Future therapy of hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S245-S252.